|Bid||20.95 x 800|
|Ask||21.05 x 800|
|Day's Range||20.83 - 22.00|
|52 Week Range||20.24 - 116.04|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.67|
Subscribe to Yahoo Finance Plus to view Fair Value for RETA
The FDA has extended the review timeline for Reata Pharmaceuticals Inc's (NASDAQ: RETA) marketing application seeking approval for omaveloxolone for Friedreich's ataxia by three months. The company recently submitted an updated Delayed-Start Analysis of the MOXIe Extension study using a March 2022 data cut-off, a new Propensity-Matched Analysis of MOXIe Extension data, and an analysis of the relevance of Nrf2, the target of omaveloxolone, to the pathophysiology of Friedreich's ataxia. Related: W
Reata (RETA) reports a wider-than-expected loss in the second quarter of 2022, while revenues miss estimates. Stock falls after updates on pipeline programs.
PLANO, Texas, August 09, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, announced that on August 8, 2022, after the U.S. financial markets closed, we received a communication from the U.S. Food and Drug Administration ("FDA") informing us that they have extended the review timeline for the New Drug Application ("NDA") for omaveloxolone for the treatment of Friedreich’s ataxia by three months.